Evidence map›Paper›PMID 30467342›Full record

Trial reportPediatric research2019

Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia.

Tamorah Lewis, William Truog, Mike Norberg, Philip L Ballard, Dara Torgerson, TOLSURF Study Group

Erratum issuedOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatric research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Influences of environmental exposures on preterm lung disease.Expert review of respiratory medicine · 2021
    Review
  5. New Pharmacologic Approaches to Bronchopulmonary Dysplasia.Journal of experimental pharmacology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tamorah LewisChildren's Mercy Hospital, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA. trlewis@cmh.edu.
William TruogChildren's Mercy Hospital, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA.
Mike NorbergChildren's Mercy Hospital, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA.
Philip L BallardDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Dara TorgersonDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
TOLSURF Study Group
Children's Mercy Hospital · USUniversity of California, San Francisco · US

Funding

Trial of Late SURFactant (TOLSURF) to Prevent BPD - Clinical Coord CtrU01HL094338 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALLARD, ROBERTA ANDERSON · 2009 to 2013
$7.4M
NHLBI NIH HHS U01 HL094338
6 · The paper itself

Abstract

backgroundBronchopulmonary dysplasia (BPD) is an orphan disease and advances in prevention and treatment are lacking. The clinical efficacy of systemic corticosteroid therapy to reduce the severity of lung disease and BPD is highly variable. Our objective was to assess whether candidate SNPs in corticosteroid metabolism and response genes are associated with short-term phenotypic response to systemic corticosteroids in infants at high risk for BPD.

methodsPharmacogenetic analysis of data from a large randomized controlled trial (TOLSURF) in infants treated with dexamethasone or hydrocortisone using multivariate linear regression. The primary outcome was a change in respiratory severity score (RSS, mean airway pressure x FiO2) at day 7 of corticosteroid treatment.

resultsrs7225082 in the intron of CRHR1 is significantly associated with the magnitude of decrease in RSS 7 days after starting treatment with systemic corticosteroid (meta-analysis P = 2.8 × 10

conclusionsGenetic variability is associated with corticosteroid responsiveness with regard to respiratory status in preterm infants. Identification of genetic markers of corticosteroid responsiveness may allow for therapeutic individualization, with the goal of optimizing the risk-to-benefit ratio for an individual child.

Indexed as

Polymorphism, Single NucleotideAdrenal Cortex HormonesBronchopulmonary DysplasiaCRF Receptor, Type 1DexamethasoneFemaleGenetic MarkersGenotypeGlucocorticoidsHumansHydrocortisoneInfant, NewbornInfant, PrematureIntronsMaleMultivariate AnalysisAdrenal Cortex HormonesCRF Receptor, Type 1DexamethasoneGenetic MarkersGlucocorticoidsHydrocortisoneReceptors, Corticotropin-Releasing HormoneSurface-Active Agents

Identifiers

PMID30467342
PMCPMC6532775
OpenAlexW2901319137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.